Calliditas Therapeutics AB

Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.

STOCKHOLM, May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 pm CET/8:30 am ET. Calliditas will also host 1x1 meetings during the conference.

Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference

Calliditas Therapeutics AB (CALT) CEO Renée Lucander on Q1 2021 Results - Earnings Call Transcript

STOCKHOLM, May 18, 2021 /PRNewswire/ -- Filing of New Drug Application submission to the FDA "Following the positive top line readout of our pivotal Phase 3 trial NefIgArd, which met both the primary and key secondary endpoints with results being statistically significant and clinically relevant we commenced the regulatory filing process which ultimately resulted in the timely filing of the submission to the FDA in Q1 as planned. In April, we received the response from the Food and Drug Administration (FDA) who accepted the submission and granted Priority Review for the New Drug Application (NDA) for Nefecon.

Interim Report Q1, 2021

STOCKHOLM, May 14, 2021 /PRNewswire/ -- On May 18 th, 2021, Calliditas Therapeutics AB (publ) ("Calliditas") will publish its financial report for the first quarter of 2021, and at 2.30 pm CET will host a conference call to present and discuss the results. The event will be hosted by the company's CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, and will be held in English.

Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021

STOCKHOLM, May 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that former Head of North America Commercial, Andrew Udell, has been promoted to President, North America, effective immediately.  "Andrew has been instrumental in the growth of the US operations over the last 12 months and has done a great job of creating a strong connection between the US and European teams throughout this period of high growth.

Calliditas promotes Andrew Udell to President, North America

STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) announces today that the Board has decided that the interim report for the first quarter 2021 will be published on May 18, 2021. The previously planned date for publication was May 13, 2021, which is the Ascension Day.

Calliditas Therapeutics AB: Change in financial calendar

STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's website: www.calliditas.com. This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act.

Calliditas Therapeutics' 2020 Annual Report Published

Calliditas Therapeutics (NASDAQ: CALT) has submitted a marketing application to the FDA seeking approval for Nefecon, an oral formulation targeting down-regulation of IgA1 for primary IgA Nephropathy (IgAN). IgAN, also known as Berger's disease, is a kidney disease that occurs when an antibody called immunoglobulin A (IgA) builds up in the kidneys, resulting in hampering the kidneys' ability to filter waste from the blood.

Calliditas Therapeutics Files US Application For Nefecon In Kidney Disease

STOCKHOLM, Feb. 18, 2021 /PRNewswire/ -- "On November 8, 2020, we announced positive topline readout of Part A of our Phase 3 pivotal trial, NefIgArd. The results were statistically significant and clinically relevant: proteinuria showed a 31% reduction versus baseline, a stronger effect...

Calliditas Therapeutics: Year-End Report, 2020

Calliditas Therapeutics AB (NASDAQ: CALT) has dosed that first patient in the global open-label extension part of Phase 3 study (dubbed as NefIgArd) that will offer a 9-month treatment with Nefecon to all qualifying patients who have completed the NefIgArd study and will evaluate the efficacy and safety of Nefecon treatment in patients with IgA Nephropathy (also known as Berger's disease) is characterized by the build-up of IgA, a protein made by the immune system to protect the body, in the kidneys, causing inflammation that damages kidney tissues.

Calliditas Starts Dosing In Nefecon Open Label Extension Study In Kidney Disease

Lockheed Martin

SNDL Inc.

Electrameccanica

Undervalued stocks that are likely to surge higher in the next few quarters supported by company specific catalysts and industry tailwinds. The post 4 Undervalued Stocks That Could Rip Higher appeared first on InvestorPlace.

4 Undervalued Stocks That Could Rip Higher

STOCKHOLM, Jan. 26, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (Nasdaq: CALT) will today launch a proposed public offering of American Depositary Shares ("ADSs"), in the United States for trading on The Nasdaq Global Select Market in the...

Calliditas Therapeutics launches proposed global offering

STOCKHOLM, Jan. 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enrolled for the global Phase 3 clinical trial NefIgArd, which investigates the effect of Nefecon® versus placebo in...

Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial

STOCKHOLM, Nov. 27, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021. The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting on September 14,...

Calliditas Therapeutics' nomination committee for the AGM 2021

BeiGene

BioNTech SE

I-Mab

Merck

Pfizer

Thermo Fisher Scientific

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck paid $2.75 billion to acquire VelosBio, a company formed in 2017 to develop ROR1 ADCs for cancer.

Week In Review: RemeGen, A Yantai Biologics Company, Completes $515 Million Hong Kong IPO

STOCKHOLM, Nov. 11, 2020 /PRNewswire/ -- On November 12, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the third quarter 2020. Calliditas will also host a telephone conference, which will include a presentation of the results, on the...

Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report

STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy (IgAN). Calliditas will...

Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial

STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (OMX Nasdaq: CALTX) (NASDAQ: CALT) ("Calliditas") today announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients...

Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Successful capital raise on NASDAQ STOCKHOLM, Aug. 13, 2020 /PRNewswire/ -- "In June we successfully closed a $90m U.S.

Calliditas Therapeutics: Interim Report Q2, 2020

STOCKHOLM, Aug. 11, 2020 /PRNewswire/ -- On August 13, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the second quarter 2020.

Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report

Calliditas Therapeutics (NASDAQ: CALT) shares are trading higher on Tuesday after Jefferies initiated coverage on the stock with a Buy rating and a price target of $44 per share.

Why Calliditas Therapeutics Stock Trading Higher Today

News for Calliditas Therapeutics AB Stock (CALT)